Research programme: therapeutic oxygen-carrying proteins - New Beta Innovation
Latest Information Update: 09 Aug 2016
At a glance
- Originator New Beta Innovation
- Class Proteins
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified
Most Recent Events
- 09 Aug 2016 Early research in Undefined indication in Hong Kong (unspecified route)